GH Research: Rapid Onset And Short Action Change The Treatment Paradigm
GH Research is developing GH001, an inhalable mebufotenin therapy aimed at treating resistant depression. The company reported strong results from its Phase 2b trial and is preparing for a global Phase 3 program in 2026. The rapid onset and short duration of the drug's effects could significantly change treatment approaches.
- ▪GH Research is advancing an inhalable mebufotenin therapy called GH001.
- ▪The Phase 2b trial results for GH001 were strong, indicating potential effectiveness.
- ▪A global Phase 3 program for GH001 is expected to begin in 2026.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906872-gh-research-rapid-onset-and-short-action-change-the-treatment-paradigm"},"author":{"@type":"Person","name":"Richard…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
